Guerbet
Guerbet, a global leader in medical imaging, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1926, the company has established itself as a pioneer in the development of contrast agents and medical imaging solutions, marking significant milestones in innovation and technology throughout its history. Specialising in imaging products for radiology and interventional imaging, Guerbet offers a diverse portfolio that includes contrast media, injectors, and software solutions. Their commitment to quality and safety sets them apart in the industry, ensuring optimal patient care and enhanced diagnostic accuracy. With a strong market position, Guerbet continues to achieve notable advancements, reinforcing its reputation as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Guerbet's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guerbet's score of 45 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Guerbet's reported carbon emissions
In 2022, Guerbet, headquartered in France, reported total greenhouse gas emissions of approximately 34,489,000 kg CO2e, encompassing Scope 1 and 2 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 27.5% by 2032, using 2021 as the baseline year. Additionally, Guerbet is committed to a 13.5% reduction in absolute Scope 3 emissions, which include emissions from purchased goods and services, fuel and energy activities, upstream transportation and distribution, waste generated in operations, and downstream transportation and distribution, also by 2032. These targets align with the Science Based Targets initiative (SBTi) and are classified as consistent with the reductions necessary to limit global warming to well below 2°C. Guerbet's commitment reflects a proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | - |
| Scope 2 | - |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guerbet is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
